Although low-dose IL-2 is promising because of its Treg-enhancing effects, its efficacy is likely constrained by the underlying immune dysfunction in ALS, which is driven by immunosenescence, metabolic dysregulation, and chronic inflammation. The gene discussed is IL2; the disease is amyotrophic lateral sclerosis.